Iambic Therapeutics, Inc.

424B4 priced

Price $16.00 · 9,375,000 shares · Gross proceeds $150,000,000

Iambic Therapeutics, Inc. reports collaboration revenue of $12.8M for H1 2026, up 225% from $3.9M in H1 2025, driven by progress in RevMed and Takeda programs and a milestone achievement. Research and development expenses surged 74% to $57.1M, with significant increases in IAM1363 program costs, discovery/platform activities, and personnel expenses. General and administrative expenses rose 37% to $9.1M. The company remains unprofitable, recording a $50.1M net loss in H1 2026, with no product sales revenue expected for the foreseeable future. Revenue from the Lundbeck Agreement is projected to reach $3.8M by 2027.

EFFECT effective

CERT inactive

8-A12B effective

S-1/A amended

Price $16.00 · Range $15.00 to $17.00 · 9,375,000 shares · Gross proceeds $150,000,000

Iambic Therapeutics, Inc. reported increased collaboration revenue of $12.8 million for the six months ended June 30, 2026, driven by progress with RevMed and Takeda agreements, compared to $3.9 million in the same period in 2025. Research and development expenses rose 74% to $57.1 million, reflecting expanded clinical trials for IAM1363 and platform development. General and administrative expenses increased 37% to $9.1 million. The company expects future revenue from collaboration milestones and royalties, with $3.8 million remaining from the Lundbeck Agreement to be recognized through 2027. No product sales revenue has been generated, and losses continue as development efforts advance.

S-1 filed

Iambic Therapeutics, Inc. has expanded its collaboration agreements with major pharmaceutical companies, including AbbVie, Takeda, Revolution Medicines, and Lundbeck, generating $12.8 million in collaboration revenue for the six months ended June 30, 2026, a 225% increase from $3.9 million in the same period in 2025. The company anticipates continued revenue growth from milestone payments and royalties but remains unprofitable, reporting a net loss of $50.1 million for the six months ended June 30, 2026. Operating expenses, primarily research and development, rose 74% year-over-year to $57.1 million, driven by expanded drug development programs and platform advancements. The company faces risks related to reliance on collaboration revenue, clinical trial uncertainties, and the inability to commercialize drug candidates.

DRS/A amended

Iambic Therapeutics, Inc. reported significant growth in collaboration revenue for the six months ended June 30, 2026, reaching $12.8 million compared to $3.9 million in the same period in 2025, driven by progress in programs with RevMed and Takeda, as well as a success-based milestone. Research and development expenses increased by 74% to $57.1 million, primarily due to expanded clinical trials for IAM1363, platform development, and increased personnel costs. General and administrative expenses rose 37% to $9.1 million, reflecting broader operational scaling. The company remains focused on advancing its HER2 program and AI-driven platform while managing ongoing financial risks.

DRS filed

Iambic Therapeutics, Inc. reports collaboration revenue from agreements with Lundbeck, RevMed, and Takeda, with $9.4 million in 2025 revenue compared to $1.2 million in 2024. The company remains in early development stages, with no product sales revenue and expects to rely on collaboration arrangements for future revenue. Significant increases in R&D expenses reflect expanded clinical programs, platform development, and partnership activities. The company faces risks related to clinical trial outcomes, revenue volatility, and dependence on third-party collaborations.